Navigation Links
Amylin Pharmaceuticals to Present at Goldman Sachs 32nd Annual Global Healthcare Conference and Jefferies Global Life Sciences Conference
Date:5/31/2011

SAN DIEGO, May 31, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Goldman Sachs 32nd Annual Global Healthcare Conference on Tuesday, June 7, 2011, at 12:20 p.m. ET / 9:20 a.m. PT in Palos Verdes, California and at the Jeffries Global Life Sciences Conference on Wednesday, June 8, 2011, at 10:00 a.m. ET / 7:00 a.m. PT in New York.  Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview at the Goldman Sachs conference.  Mark Foletta, senior vice president, finance and chief financial officer of Amylin, will provide a corporate overview at the Jeffries conference.

The presentations will be webcast live through the "Investors" section of Amylin's corporate website at www.amylin.com, and the recordings will be made available on the website following the events. To access the live webcasts, please log on to Amylin's website approximately fifteen minutes prior to the presentations to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin to Advance Key Value-Driving Opportunities in 2011
2. Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin
3. Amylin Pharmaceuticals to Present at the Citi 7th Annual US Small/Mid Cap Conference
4. Amylin Pharmaceuticals Announces Third Quarter Product Revenues; Quarterly Update Conference Call Canceled
5. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
6. Amylin Pharmaceuticals to Present at the 2010 Jefferies Global Life Sciences Conference
7. Amylin Pharmaceuticals to Present at the 2010 Citi Investment Research Global Healthcare Conference
8. Amylin Pharmaceuticals to Present at the Deutsche Bank 35th Annual Healthcare Conference
9. Amylin Pharmaceuticals to Webcast Third Quarter Results
10. Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009
11. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... and CARDIFF, UK (PRWEB) , ... June 23, 2017 , ... ... and Brian Lula, president of Physik Instrumente USA, have been selected as this year’s ... photonics . , The two have been invited along with other honorees to accept ...
(Date:6/22/2017)... ... 2017 , ... Beaker, the industry’s pioneer in developing customizable ... industry, today announces a strategic partnership with Alcami Corporation, a leading global Contract ... expertise in executive recruitment solutions, providing Alcami with access to the best talent ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... specialists DST Diagnostische Systeme & Technologien GmbH, thereby expanding its product portfolio to ... from hay fever, urticaria, asthma, atopic eczema or a food allergy. Allergies are ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... clients throughout the biopharma and life sciences industries, continue to be in demand ... Tunnell’s Kip Wolf will be speaking on “The State of Information Governance in ...
Breaking Biology Technology:
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
Breaking Biology News(10 mins):